This item is non-discoverable

IRURETAGOYENA BRUCE, MIRENTXU INES

Preferred name

Official Name

IRURETAGOYENA BRUCE, MIRENTXU INES

Main Affiliation

Facultad de Medicina Clínica Alemana Universidad del Desarrollo

mirentxu@udd.cl

Scopus Author ID

10044734400

Now showing 1 - 9 of 9

Some of the metrics are blocked by your
consent settings
Respuesta inmunitaria al SARS-CoV-2 y factores asociados previo a la vacunación, en personal de salud de atención primaria en una comuna de Santiago, Chile
(2022)
OLEA NORMANDIN, ANDREA MARIA
;
Elena Pedroni
;
HIRMAS ADAUY, MACARENA SOLEDAD
;
MATUTE WILLEMSEM, MARIA ISABEL
;
IRURETAGOYENA BRUCE, MIRENTXU INES
Scopus© Citations 1 1
Some of the metrics are blocked by your
consent settings
Vitamin D supplementation reduces TLR7 and TLR9 expression in B cells from systemic lupus erythematosus patients
(2019)
IRURETAGOYENA BRUCE, MIRENTXU INES
;
Naves, R.
;
Hirigoyen, D
;
Burgos, P. I.
4
Some of the metrics are blocked by your
consent settings
Enfermedad relacionada a IgG4. Serie clínica de pacientes chilenos
(2022)
María C. Cuéllar
;
Miguel Gutiérrez
;
Alejandra Herrera
;
Fabián Elgueta
;
Pamela Wurmann
Scopus© Citations 1 4
Some of the metrics are blocked by your
consent settings
Longitudinal assessment of SARS-CoV-2 IgG seroconversionamong front-line healthcare workers during the first wave of the Covid-19 pandemic at a tertiary-care hospital in Chile
(2021)
IRURETAGOYENA BRUCE, MIRENTXU INES
;
Macarena R. Vial
;
Maria Spencer-Sandino
;
Pablo Gaete
;
Anne Peters
<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Healthcare workers (HCWs) are at high risk of exposure to SARS-CoV-2. Cross-sectional studies have provided variable rates of seroprevalence in HCWs. Longitudinal assessments of the serological response to Covid-19 among HCWs are crucial to understanding the risk of infection and changes in antibody titers over time. We aimed to investigate seroprevalence and risk factors associated with seroconversion in a prospective cohort of HCWs during the peak of the first wave of the Covid-19 pandemic.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>We conducted a longitudinal study among 446 front-line HCWsin a tertiary-care hospital in Chile from April to July 2020. IgG was determined monthly using two different ELISAs in serum samples of HCWs, during the three-month period. In each visit, demographic data, symptoms, risk factors, and exposure risks were also assessed.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>The overall seroprevalence at the end of the study period was 24% (95% CI20.2–28.3), with 43% of seropositive HCWs reporting no prior symptoms. Seroconversion rates significantly differed over the study period, from 2.1% to as high as 8.8% at the peak of the epidemic. There were no statistically significant differences observed between HCWs in direct clinical care of patients with Covid-19 and those working in low risk areas. Antibody titers appeared to wane over time.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>HCWs were severely affected with a high rate of seroconversion that appeared to mirror the local epidemiological situation. A significant amount of participants underwent an asymptomatic infection, highlighting the need for improved surveillance policies. Antibody titers appear to wane over time; further studies to understand this finding’s impact on the risk of reinfection are warranted.</jats:p> </jats:sec>
1Scopus© Citations 21 2
Some of the metrics are blocked by your
consent settings
Comparative evaluation of four rapid SARS-CoV-2 antigen detection tests using universal transport medium
(2021)
WEITZEL, THOMAS
;
LEGARRAGA RADDATZ, PAULETTE
;
IRURETAGOYENA BRUCE, MIRENTXU INES
;
Gabriel Pizarro
;
Valeska Vollrath
42 1Scopus© Citations 46
Some of the metrics are blocked by your
consent settings
Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples
(2020)
PORTE TORRE, LORENA ISABEL
;
LEGARRAGA RADDATZ, PAULETTE
;
Sabine Dittrich
;
Valeska Vollrath
;
AGUILERA SANHUEZA, XIMENA PAZ
15Scopus© Citations 278
Some of the metrics are blocked by your
consent settings
Integration of T‐cell clonality screening using <scp>TRBC</scp>‐1 in lymphoma suspect samples by flow cytometry
(2023)
Felipe Castillo
;
Constanza Morales
;
Biserka Spralja
;
Joaquín Díaz‐Schmidt
;
IRURETAGOYENA BRUCE, MIRENTXU INES
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>The diagnosis of T‐cell non‐Hodgkin lymphomas (NHL) is challenging. The development of a monoclonal antibody specific for T‐cell receptor β constant region 1 (TRBC1) provides an alternative to discriminate clonal T cells. The aim of this study was to evaluate the diagnostic potential of an anti‐TRBC1 mAb for the identification of T‐NHL.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We performed a cross‐sectional diagnostic analytic study of samples tested for lymphoma. All samples sent for lymphoma screening were first evaluated using the standard Euroflow LST, to which a second additional custom‐designed T‐cell clonality assessment tube was added CD45/TRBC1/CD2/CD7/CD4/TCRγδ/CD3. Flow cytometry reports were compared with morphological and molecular tests.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Fifty‐nine patient samples were evaluated. Within the T‐cell population, cut‐off percentages in the CD4+ cells were from 29.4 to 54.6% and from 23.9 to 52.1% in CD8+ cells. Cut‐off ratios in CD4+ T cells were from 0.33 to 1.1, and in CD8+ cells between 0.22 and 1.0. Using predefined normal cut‐off values, 18 of 59 (30.5%) samples showed a restricted expression of TRBC1. A final diagnosis of a T‐NHL was confirmed clinically and/or by histopathological studies in 15 of the 18 cases (83.3%). There were no cases of T‐NHL by morphology/IHC with normal TRBC1 expression. Non‐neoplastic patient samples behaved between predefined TRBC1 cut‐off values.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Expression of TRBC1 provides a robust method for T‐cell clonality assessment, with very high sensitivity and good correlation with complementary methods. TRBC1 can be integrated into routine lymphoma screening strategies via flow cytometry.</jats:p></jats:sec>
Scopus© Citations 3 1
Some of the metrics are blocked by your
consent settings
First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia
(2020)
VALENZUELA LETELIER, OMAR ANTONIO
;
IBAÑEZ, SEBASTIAN
;
M. Cecilia Poli
;
ROESSLER VERGARA, PATRICIA ANDREA
;
AYLWIN RAMIREZ, MABEL CRISTINA
12 1Scopus© Citations 5
Some of the metrics are blocked by your
consent settings
Evaluation of two fluorescence immunoassays for the rapid detection of SARS-CoV-2 antigen—new tool to detect infective COVID-19 patients
(2021)
PORTE TORRE, LORENA ISABEL
;
LEGARRAGA RADDATZ, PAULETTE
;
IRURETAGOYENA BRUCE, MIRENTXU INES
;
Valeska Vollrath
;
Gabriel Pizarro
<jats:sec> <jats:title>Background</jats:title> <jats:p>Real-Time Reverse-Transcription Polymerase Chain Reaction (RT-PCR) is currently the only recommended diagnostic method for SARS-CoV-2. However, rapid immunoassays for SARS-CoV-2 antigen could significantly reduce the COVID-19 burden currently weighing on laboratories around the world.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>We evaluated the performance of two rapid fluorescence immunoassays (FIAs), SOFIA SARS Antigen FIA (Quidel Corporation, San Diego, CA, USA) and STANDARD F COVID-19 Ag FIA (SD Biosensor Inc., Gyeonggi-do, Republic of Korea), which use an automated reader. The study used 64 RT-PCR characterized clinical samples (32 positive; 32 negative), which consisted of nasopharyngeal swabs in universal transport medium.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Of the 32 positive specimens, all from patients within 5 days of symptom onset, the Quidel and SD Biosensor assays detected 30 (93.8%) and 29 (90.6%) samples, respectively. Among the 27 samples with high viral loads (Ct ≤ 25), the two tests had a sensitivity of 100%. Specificity was 96.9% for both kits.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>The high performance of the evaluated FIAs indicates a potential use as rapid and PCR-independent tools for COVID-19 diagnosis in early stages of infection. The excellent sensitivity to detect cases with viral loads above ~10<jats:sup>6</jats:sup> copies/mL (Ct values ≤ 25), the estimated threshold of contagiousness, suggests that the assays might serve to rapidly identify infective individuals.</jats:p> </jats:sec>
1Scopus© Citations 21

IRURETAGOYENA BRUCE, MIRENTXU INES

Filters

Settings

Sort By

Results per page